Drug Profile

STAR 0310

Alternative Names: ISB-830-X8; STAR-0310; STR-310

Latest Information Update: 02 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Ichnos Sciences
Developer BioCryst Pharmaceuticals; Ichnos Sciences
Class Anti-inflammatories; Monoclonal antibodies; Skin disorder therapies
Mechanism of Action OX40 receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Atopic dermatitis
Preclinical Unspecified

Most Recent Events

23 Jan 2026 Astria Therapeutics has been acquired and merged into BioCryst Pharmaceuticals
17 Sep 2025 Adverse events, pharmacokinetics and pharmacodynamics data from a phase Ia trial in Healthy volunteers released by Astria Therapeutics
05 Mar 2025 9436383 - No updates

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com